These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 23311125)

  • 1. Earlobe sarcoidosis.
    Vorselaars AD; Keijsers RG; Grutters JC
    Sarcoidosis Vasc Diffuse Lung Dis; 2012 Mar; 29(1):55-7. PubMed ID: 23311125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 18F-FDG PET in sarcoidosis: an observational study in 12 patients treated with infliximab.
    Keijsers RG; Verzijlbergen JF; van Diepen DM; van den Bosch JM; Grutters JC
    Sarcoidosis Vasc Diffuse Lung Dis; 2008 Dec; 25(2):143-9. PubMed ID: 19382534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of infliximab biosimilar Inflectra
    Schimmelpennink MC; Vorselaars ADM; van Beek FT; Crommelin HA; Deneer VHM; Keijsers RGM; Veltkamp M
    Respir Med; 2018 May; 138S():S7-S13. PubMed ID: 29496351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 18F-FDG PET as a predictor of pulmonary function in sarcoidosis.
    Keijsers RG; Verzijlbergen EJ; van den Bosch JM; Zanen P; van de Garde EM; Oyen WJ; Grutters JC
    Sarcoidosis Vasc Diffuse Lung Dis; 2011 Oct; 28(2):123-9. PubMed ID: 22117503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of infliximab in a patient with refractory idiopathic retroperitoneal fibrosis.
    Catanoso MG; Spaggiari L; Magnani L; Pipitone N; Versari A; Boiardi L; Pazzola G; Pattacini P; Salvarani C
    Clin Exp Rheumatol; 2012; 30(5):776-8. PubMed ID: 23021007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Refractory polymyalgia rheumatica as presenting manifestation of large-vessel vasculitis associated to sarcoidosis. Successful response to adalimumab.
    Bejerano C; Blanco R; González-Vela C; Agüero R; Carril JM; González-Gay MA
    Clin Exp Rheumatol; 2012; 30(1 Suppl 70):S94-7. PubMed ID: 22410180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of the TNF-α inhibitor adalimumab in patients with recalcitrant sarcoidosis: a prospective observational study using FDG-PET.
    Milman N; Graudal N; Loft A; Mortensen J; Larsen J; Baslund B
    Clin Respir J; 2012 Oct; 6(4):238-47. PubMed ID: 22128762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of relapse after discontinuation of infliximab therapy in severe sarcoidosis.
    Vorselaars AD; Verwoerd A; van Moorsel CH; Keijsers RG; Rijkers GT; Grutters JC
    Eur Respir J; 2014 Feb; 43(2):602-9. PubMed ID: 23988768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypercalcemia from sarcoidosis successfully treated with infliximab.
    Huffstutter JG; Huffstutter JE
    Sarcoidosis Vasc Diffuse Lung Dis; 2012 Mar; 29(1):51-2. PubMed ID: 23311123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of infliximab in refractory FDG PET-positive sarcoidosis.
    Vorselaars AD; Crommelin HA; Deneer VH; Meek B; Claessen AM; Keijsers RG; van Moorsel CH; Grutters JC
    Eur Respir J; 2015 Jul; 46(1):175-85. PubMed ID: 25929955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative evaluation of 18F-FDG PET and 67Ga scintigraphy in patients with sarcoidosis.
    Nishiyama Y; Yamamoto Y; Fukunaga K; Takinami H; Iwado Y; Satoh K; Ohkawa M
    J Nucl Med; 2006 Oct; 47(10):1571-6. PubMed ID: 17015889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beneficial effect of infliximab on refractory sarcoidosis.
    Ørum M; Hilberg O; Krag S; Bendstrup E
    Dan Med J; 2012 Dec; 59(12):A4535. PubMed ID: 23290282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Follow-up of muscular sarcoidosis using fluorodeoxyglucose positron emission tomography.
    Marie I; Lahaxe L; Vera P; Edet-Samson A
    QJM; 2010 Dec; 103(12):1000-2. PubMed ID: 20385567
    [No Abstract]   [Full Text] [Related]  

  • 14. Infliximab for refractory sarcoidosis.
    Baughman RP; Lower EE
    Sarcoidosis Vasc Diffuse Lung Dis; 2001 Mar; 18(1):70-4. PubMed ID: 11354550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [TNFα blocking agents and sarcoidosis: an update].
    Toussirot E; Pertuiset E
    Rev Med Interne; 2010 Dec; 31(12):828-37. PubMed ID: 20510487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of [18F]-fluorodeoxyglucose ([18F]-FDG) imaging in sarcoidosis: unsuspected neurosarcoidosis discovered by [18F]-FDG PET and early metabolic response to corticosteroid therapy.
    Aide N; Benayoun M; Kerrou K; Khalil A; Cadranel J; Talbot JN
    Br J Radiol; 2007 Mar; 80(951):e67-71. PubMed ID: 17548505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial.
    Judson MA; Baughman RP; Costabel U; Flavin S; Lo KH; Kavuru MS; Drent M;
    Eur Respir J; 2008 Jun; 31(6):1189-96. PubMed ID: 18256069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiac sarcoidosis mimicking non-ST-elevation myocardial infarction.
    Uijlings R; Balt JC; Boom P; Wever E
    J Cardiovasc Med (Hagerstown); 2012 Apr; 13(4):277-80. PubMed ID: 20508527
    [No Abstract]   [Full Text] [Related]  

  • 19. Heterogeneous myocardial FDG uptake and the disease activity in cardiac sarcoidosis.
    Tahara N; Tahara A; Nitta Y; Kodama N; Mizoguchi M; Kaida H; Baba K; Ishibashi M; Hayabuchi N; Narula J; Imaizumi T
    JACC Cardiovasc Imaging; 2010 Dec; 3(12):1219-28. PubMed ID: 21163450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Refractory multisystem sarcoidosis responding to infliximab therapy.
    Croft AP; Situnayake D; Khair O; Giovanni G; Carruthers D; Sivaguru A; Gordon C
    Clin Rheumatol; 2012 Jun; 31(6):1013-8. PubMed ID: 22249374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.